Application of polygenic risk score and genetic risk score in estimation of hypertension manifestation and drug response. It has been reported that five loci (PKD2L1, SLC12A2, CACNA1C, CACNB4, and CA7) are drug targets for hypertension medications. More than 1000 BP-determining loci have now been identified and drug-target genes are expected to expand in the future. This evidence concerns the gene PKD2L1 and hypertensive disorder.